

8-K 1 cenb20160608\_8k.htm FORM 8-K

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K****CURRENT REPORT****PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934****Date of Report (Date of earliest event reported): June 6, 2016****CEN BIOTECH, INC.**

(Exact name of registrant as specified in its charter)

Ontario, Canada

(State or other jurisdiction of  
incorporation)

000-55557

(Commission File Number)

(I.R.S. Employer Identification  
Number)20 North Rear Road, Lakeshore, Ontario, Canada N0R 1K0

(Address of principal executive offices)

Registrant's telephone number, including area code

226-344-0660

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Unless otherwise indicated, in this Form 8-K, references to "we," "our," "us," the "Company," "CEN" or the "Registrant" refer to CEN Biotech, Inc.

**Item 7.01 Regulation FD Disclosure.**

On June 6, 2016, the Company issued a press release announcing the Company's discontinuance of the Application for Judicial Review ('AJR') filed in Canadian Federal Court., a copy of which is attached as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release dated June 6, 2016 CEN Biotech Inc. Shareholder Update

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 8, 2016

CEN Biotech, Inc.  
(Registrant)

/s/ Bill Chaaban  
BILL CHAABAN  
Chief Executive Officer